A Birth-cohort testing intervention identified hepatitis c virus infection among patients with few identified risks: A crosssectional study

BMC Infectious Diseases

Volumn 15, Issue 1, 2015, Pages

  Southern, William N ^a,b   Norton, Brianna ^b,c   Steinman, Meredith ^b,c   DeLuca, Joseph ^b,c   Drainoni, Mari Lynn ^d   Smith, Bryce D ^e   Litwin, Alain H ^b,c  

^a Division of Regenerative Medicine   (United States)

^b MONTEFIORE MEDICAL CENTER   (United States)

^c Division of General Internal Medicine   (United States)

^d BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Hepatitis C virus; Risk assessment; Screening; Testing strategies

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS ANTIBODY; HEPATITIS C ANTIBODY;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH CARE SYSTEM; HEPATITIS C; HEPATITIS C VIRUS; HIGH RISK BEHAVIOR; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SUBSTANCE ABUSE; UNITED STATES; BLOOD; CLINICAL TRIAL; HEPACIVIRUS; IMMUNOLOGY; MASS SCREENING; MIDDLE AGED; MULTICENTER STUDY; NEW YORK; PATHOGENICITY; PROCEDURES;

ADULT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEW YORK; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84949255808     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/s12879-015-1283-3     Document Type: Article

References (37)

1. Denniston MM, Jiles RB, Drobeniuc J, Klevens RM, Ward JW, McQuillan GM, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Annals of internal medicine. 2014;160(5):293-300.
2. Chak E, Talal AH, Sherman KE, Schiff ER, Saab S. Hepatitis C virus infection in USA: an estimate of true prevalence. Liver international: official journal of the International Association for the Study of the Liver. 2011;31(8):1090-101.
3. Rein DB, Wittenborn JS, Weinbaum CM, Sabin M, Smith BD, Lesesne SB. Forecasting the morbidity and mortality associated with prevalent cases of pre-cirrhotic chronic hepatitis C in the United States. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2011;43(1):66-72.
4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358(9286):958-65.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. NEnglJMed. 2002;347(13):975-82.
6. Hadziyannis SJ, Sette H, Jr., Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-55.
7. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2004;39(4):1147-71.
8. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335-74.
9. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1998;47(RR-19):1-39.
10. EASL International Consensus Conference on hepatitis C. Paris, 26-27 February 1999 Consensus statement. J Hepatol. 1999;30(5):956-61.
11. Galmiche JP. French consensus conference on hepatitis C: screening and treatment. Gut. 1998;42(6):892-8.
12. National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C:2002-June 10-12, 2002. Hepatology. 2002;36:s3-s20.
13. Southern WN, Drainoni ML, Smith BD, Christiansen CL, McKee D, Gifford AL, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. Journal of viral hepatitis. 2011;18(7):474-81.
14. Roblin DW, Smith BD, Weinbaum CM, Sabin ME. HCV screening practices and prevalence in an MCO, 2000-2007. The American journal of managed care. 2011;17(8):548-55.
15. Spradling PR, Rupp L, Moorman AC, Lu M, Teshale EH, Gordon SC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2012;55(8):1047-55.
16. Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR. Recommendations and reports: Morbidity and mortality weekly report. Recommendations and reports /Centers for Disease Control. 2012;61(RR-4):1-32.
17. Smith BD, Beckett GA, Yartel A, Holtzman D, Patel N, Ward JW. Previous exposure to HCV among persons born during 1945-1965: prevalence and predictors, United States, 1999-2008. American journal of public health. 2014;104(3):474-81.
18. Smith BD, Patel N, Beckett GA, Jewett A, Ward JW. Hepatitis C virus antibody prevalence, correlates and predictors among persons born from 1945 through 1965, United States, 1999-2008. Hepatology. 2011;54:4(Suppl): 554A-555A.
19. Tomaszewski KJ, Deniz B, Tomanovich P, Graham CS. Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. American journal of public health. 2012;102(11):e101-106.
20. Smith BD, Yartel AK. Comparison of hepatitis C virus testing strategies: birth cohort versus elevated alanine aminotransferase levels. American journal of preventive medicine. 2014;47(3):233-41.
21. Drainoni ML, Litwin AH, Smith BD, Koppelman EA, McKee MD, Christiansen CL, et al. Effectiveness of a risk screener in identifying hepatitis C virus in a primary care setting. American journal of public health. 2012;102(11):e115-121.
22. Litwin AH, Smith BD, Drainoni ML, McKee D, Gifford AL, Koppelman E, et al. Primary care-based interventions are associated with increases in hepatitis C virus testing for patients at risk. Digestive and liver disease: official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2012;44(6):497-503.
23. Thomas DL, Cannon RO, Shapiro CN, Hook III EW, Alter MJ, Quinn TC. Hepatitis C, hepatitis B, and human immunodeficiency virus infections among non-intravenous drug-using patients attending clinics for sexually transmitted diseases. J Infect Dis. 1994;169(5):990-5.
24. Thomas DL, Zenilman JM, Alter HJ, Shih JW, Galai N, Carella AV, et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore-an analysis of 309 sex partnerships. J Infect Dis. 1995;171(4):768-75.
25. Rosman AS, Waraich A, Galvin K, Casiano J, Paronetto F, Lieber CS. Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol. 1996;91(3):498-505.
26. Rosman AS, Paronetto F, Galvin K, Williams RJ, Lieber CS. Hepatitis C virus antibody in alcoholic patients. Association with the presence of portal and/or lobular hepatitis. Archives of internal medicine. 1993;153(8):965-9.
27. Schaefer M, Capuron L, Friebe A, Diez-Quevedo C, Robaeys G, Neri S, et al. Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement. J Hepatol. 2012;57(6):1379-90.
28. Raja M, Azzoni A, Pucci D. Characteristics of HCV positive patients in an Italian urban psychiatric unit. Clinical practice and epidemiology in mental health: CP & EMH. 2006;2:26.
29. Prati D, Taioli E, Zanella A, Della TE, Butelli S, Del VE, et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med. 2002;137(1):1-10.
30. Pratt DS, Kaplan MM. Evaluation of abnormal liver-enzyme results in asymptomatic patients. N Engl J Med. 2000;342(17):1266-71.
31. Clinical Classifications Software. Healthcare Cost and Utilization Project (HCUP) website Of the Agency for Healthcare Quality and Research (AHRQ). 2007 http://www.hcup-us.ahrq.gov/toolssoftware/ccs/ccs.jsp.
32. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, et al. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: a qualitative exploration. AIDS patient care and STDs. 2010;24(12):753-62.
33. Shakil AO, Conry-Cantilena C, Alter HJ, Hayashi P, Kleiner DE, Tedeschi V, et al. The Hepatitis C Study Group, et al. Volunteer blood donors with antibody to hepatitis C virus: clinical, biochemical, virologic, and histologic features. Annals of internal medicine. 1995;123(5):330-7.
34. Seeff LB. Natural history of hepatitis C. Hepatology. 1997;26(3 Suppl 1):21S-8S.
35. Hagan LM, Schinazi RF. Best strategies for global HCV eradication. Liver international: official journal of the International Association for the Study of the Liver. 2013;33 Suppl 1:68-79.
36. Rein DB, Smith BD, Wittenborn JS, Lesesne SB, Wagner LD, Roblin DW, et al. The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Annals of internal medicine. 2012;156(4):263-70.
37. McGarry LJ, Pawar VS, Panchmatia HR, Rubin JL, Davis GL, Younossi ZM, et al. Economic model of a birth cohort screening program for hepatitis C virus. Hepatology. 2012;55(5):1344-55.